News related to Mylotarg (Gemtuzumab Ozogamicin) and/or conditions it is approved for
Researchers Identify Mutations That Cause Blood Cancer Acute Myeloid Leukemia (AML)
Source: Blood / Hematology News From Medical News Today [2013.05.03]
A group of researchers has just identified all of the genetic mutations that cause blood cancer acute myeloid leukemia (AML), which could help drive further research for newer and better treatments for AML. The research, which was published online in The New England Journal of Medicine, could help base treatments for AML according to the genetic profile of the patient's cancer...
Computer Scientists Assemble The Most Complete Genetic Profile Yet Of Acute Myeloid Leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.05.03]
Powerful data-sifting algorithms developed by computer scientists at Brown University are helping to untangle the profoundly complex genetics of cancer. In a study reported today in the New England Journal of Medicine, researchers from Washington University in St...
Prevention Hope For Acute Myeloid Leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.04.19]
Researchers from the RIKEN Center for Integrative Medical Sciences in Japan have reported that they have identified a compound that could be used as a new treatment to prevent relapse in acute myeloid leukemia patients. In a study published in Science Translational Medicine, they show that this compound reduces the risk of relapse in a mouse model of the human disease...
Possible New Acute Leukemia Marker Treatment Target Identified
Source: Genetics News From Medical News Today [2013.05.15]
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML). The study was led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G...
|
